RT Journal Article
SR Electronic
T1 Negative regulation of <em>ACE2</em> by interferons <em>in vivo</em> and its genetic control
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.26.20080408
DO 10.1101/2020.04.26.20080408
A1 M. Azim Ansari
A1 Emanuele Marchi
A1 Narayan Ramamurthy
A1 Dominik Aschenbrenner
A1 Carl-Philipp Hackstein
A1 STOP-HCV consortium, ISARIC-4C Investigators
A1 Shang-Kuan Lin
A1 Rory Bowden
A1 Eshita Sharma
A1 Vincent Pedergnana
A1 Suresh Venkateswaran
A1 Subra Kugathasan
A1 Angela Mo
A1 Greg Gibson
A1 Graham Cooke
A1 John McLauchlan
A1 Eleanor Barnes
A1 John Kenneth Baillie
A1 Sarah Teichmann
A1 Alex Mentzer
A1 John Todd
A1 Julian Knight
A1 Holm Uhlig
A1 Paul Klenerman
YR 2020
UL http://medrxiv.org/content/early/2020/06/08/2020.04.26.20080408.abstract
AB The SARS-CoV-2 pandemic has resulted in widespread morbidity and mortality globally. ACE2 is a receptor for SARS-CoV-2 and differences in expression may affect susceptibility to COVID-19. Using HCV-infected liver tissue from 195 individuals, we discovered that among genes negatively correlated with ACE2, interferon signalling pathways were highly enriched and observed down-regulation of ACE2 after interferon-alpha treatment. Negative correlation was also found in the gastrointestinal tract and in lung tissue from a murine model of SARS-CoV-1 infection suggesting conserved regulation of ACE2 across tissue and species. Performing a genome-wide eQTL analysis, we discovered that polymorphisms in the interferon lambda (IFNL) region are associated with ACE2 expression. Increased ACE2 expression in the liver was also associated with age and presence of cirrhosis. Polymorphisms in the IFNL region may impact not only antiviral responses but also ACE2 with potential consequences for clinical outcomes in distinct ethnic groups and with implications for therapeutic interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to thank Gilead Sciences for the provision of samples and data from the BOSON clinical study for use in these analyses. The authors would also like to thank HCV Research UK (funded by the Medical Research Foundation) for their assistance in handling and coordinating the release of samples for these analyses. The authors would also like to thank ISARIC-4C investigators for their discussion and contributions to this study. This work was funded by a grant from the Medical Research Council (MR/K01532X/1-STOP-HCV Consortium). The work was supported by Core funding to the Wellcome Centre for Human Genetics provided by the Wellcome Trust (203141/Z/16/Z). This work was also supported by the Medical Research Council [grant number MC_PC_19059] and a strategic award from the Wellcome Trust (211276/Z/18/Z-WSSS). MAA is supported by a Wellcome Trust Sir Henry Dale Fellowship (220171/Z/20/Z). PK is supported as a Wellcome Trust Senior Investigator (WT 109965MA) and an NIHR Senior Investigator. PK is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. EB was funded by the Medical Research Council UK, the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The work was also supported by the NIHR Biomedical Research Centre, Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BOSON study protocol was approved by each institution review board or ethics committee before study initiation. The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice Guidelines and the Declaration of Helsinki (clinical trial registration number: NCT01962441).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe liver gene expression read counts are submitted to Gene Expression Omnibus (GEO) under accession number GSE149601. The raw FASTQ files are currently being deposited in the European Genome-phenome Archive and the accession number will be provided when the submission is finalised. Human genotype data underlying this manuscript are deposited in the European Genome-phenome Archive under accession code EGAS00001002324. Due to patient privacy concerns the gene expression FASTQ files and the human genotype data can only be accessed by making an application to the data access committee. The Information on access to the study data is available at http://www.stop-hcv.ox.ac.uk/data-access. http://www.stop-hcv.ox.ac.uk/data-access